Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.

By H. Kantarjian, S. O'brien, T. Smith, J. Cortes, F. Giles, M. Beran, S. Pierce, Y. Huh, Michael Andreeff, C. Koller and 4 more. Journal of Clinical Oncology, 2000

786 citations recorded by the source corpus.

Subfields: Genetics, Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/d48ee711a2b585064a85ab9d82192ff697e2b5f6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Goldstone
2. S. Richards
3. A. Burnett
4. M. Tallman
5. H. Lazarus
6. R. Chopra
7. G. Buck
8. I. Franklin

Citations in the corpus

• Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia (2004, neutral): “18 Precursor B-cell ALL 21/21 100 45 CALLA 149/159 94 38 Null 8/12 67 25 Karyotype Ph positive 44/48 92 12 t(8;14), t(2;8), t(8;22) 14/15 93 0.”
• Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. (2003, neutral): “9 [15,2-20] .”
• Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. (2005, background): “Although other cytogenetic features clearly have prognostic significance—especially t(4;11), t(8;14), t(1;19), and t(10;14) and structural abnormalities such as 9p, 6q, 7 or 8, and 12p19,20—these factors were not prospectively written into this study when it was designed in the early 1990s.”